BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O’Connor A, Molina-Infante J, Gisbert JP, O’Morain C. Treatment of Helicobacter pylori infection 2013. Helicobacter. 2013;18 Suppl 1:58-65. [PMID: 24011247 DOI: 10.1111/hel.12075] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Özbalcı GS, Yürüker SS, Tarım İA, Çınar H, Polat AK, Özbalcı AB, Karabulut K, Erzurumlu K. First-line therapy in Helicobacter pylori eradication therapy: experience of a surgical clinic. Ulus Cerrahi Derg 2014;30:133-7. [PMID: 25931914 DOI: 10.5152/UCD.2014.2678] [Reference Citation Analysis]
2 Abu-Qatouseh L, Abu-Sini M, Mayyas A, Al-Hiari Y, Darwish R, Aburjai T. Synthesis of New Nitrofluoroquinolone Derivatives with Novel Anti-Microbial Properties against Metronidazole Resistant H. pylori. Molecules 2017;22:E71. [PMID: 28054994 DOI: 10.3390/molecules22010071] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
3 Alhooei S, Tirgar Fakheri H, Hosseini V, Maleki I, Taghvaei T, Valizadeh SM, Bari Z. A Comparison between Hybrid and Concomitant Regimens for Helicobacter Pylori Eradication: A Randomized Clinical Trial. Middle East J Dig Dis. 2016;8:219-225. [PMID: 27698972 DOI: 10.15171/mejdd.2016.24] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
4 Keogan DM, Twamley B, Fitzgerald-hughes D, Griffith DM. Novel class of Bi( iii ) hydroxamato complexes: synthesis, urease inhibitory activity and activity against H. pylori. Dalton Trans 2016;45:11008-14. [DOI: 10.1039/c5dt05061h] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
5 Thamphiwatana S, Gao W, Obonyo M, Zhang L. In vivo treatment of Helicobacter pylori infection with liposomal linolenic acid reduces colonization and ameliorates inflammation. Proc Natl Acad Sci U S A. 2014;111:17600-17605. [PMID: 25422427 DOI: 10.1073/pnas.1418230111] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 7.3] [Reference Citation Analysis]
6 Rakici H, Akdogan RA, Ayaz T, Bedir R. Is There Any Advantage of Treating Partners in Helicobacter pylori Eradication? Gastroenterol Res Pract 2015;2015:706507. [PMID: 25861262 DOI: 10.1155/2015/706507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Kang S, Guo Y, Rao J, Jin H, You HJ, Ji GE. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus plantarum pH3A, monolaurin, and grapefruit seed extract. Food Funct 2021;12:11024-32. [PMID: 34657941 DOI: 10.1039/d1fo01480c] [Reference Citation Analysis]
8 Galal AMF, Mohamed HS, Abdel-Aziz MM, Hanna AG. Development, synthesis, and biological evaluation of sulfonyl-α-l-amino acids as potential anti-Helicobacter pylori and IMPDH inhibitors. Arch Pharm (Weinheim) 2021;354:e2000385. [PMID: 33576040 DOI: 10.1002/ardp.202000385] [Reference Citation Analysis]
9 Silva FM, Queiroz EC, Navarro-Rodriguez T, Barbuti RC, Mattar R, Iriya K, Lee JH, Eisig JN. Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers. Clinics (Sao Paulo) 2015;70:318-21. [PMID: 26039946 DOI: 10.6061/clinics/2015(05)02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Lien HM, Wu HY, Hung CL, Chen CJ, Wu CL, Chen KW, Huang CL, Chang SJ, Chen CC, Lin HJ, Lai CH. Antibacterial activity of ovatodiolide isolated from Anisomeles indica against Helicobacter pylori. Sci Rep 2019;9:4205. [PMID: 30862888 DOI: 10.1038/s41598-019-40735-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Liao WC, Huang MZ, Wang ML, Lin CJ, Lu TL, Lo HR, Pan YJ, Sun YC, Kao MC, Lim HJ, Lai CH. Statin Decreases Helicobacter pylori Burden in Macrophages by Promoting Autophagy. Front Cell Infect Microbiol 2016;6:203. [PMID: 28144585 DOI: 10.3389/fcimb.2016.00203] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
12 Gisbert JP, Barrio J, Modolell I, Molina-Infante J, Aisa AP, Castro-Fernández M, Rodrigo L, Cosme A, Gisbert JL, Fernández-Bermejo M, Marcos S, Marín AC, McNicholl AG. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. Dig Dis Sci 2015;60:458-64. [PMID: 25236423 DOI: 10.1007/s10620-014-3365-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
13 Tai WC, Lee CH, Chiou SS, Kuo CM, Kuo CH, Liang CM, Lu LS, Chiu CH, Wu KL, Chiu YC. The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication. PLoS One. 2014;9:e105822. [PMID: 25141137 DOI: 10.1371/journal.pone.0105822] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
14 Wang B, Wang YH, Lv ZF, Xiong HF, Wang H, Yang Y, Xie Y. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter. 2015;20:79-88. [PMID: 25381839 DOI: 10.1111/hel.12180] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
15 Keogan DM, Griffith DM. Current and potential applications of bismuth-based drugs. Molecules 2014;19:15258-97. [PMID: 25251194 DOI: 10.3390/molecules190915258] [Cited by in Crossref: 81] [Cited by in F6Publishing: 58] [Article Influence: 10.1] [Reference Citation Analysis]
16 Alvi S, Javeed A, Akhtar B, Sharif A, Akhtar MF. Probiotics for cure of Helicobacter pylori infection: A review. International Journal of Food Properties 2017;20:2215-22. [DOI: 10.1080/10942912.2016.1233432] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
17 Ruggiero P. Use of probiotics in the fight against Helicobacter pyloriWorld J Gastrointest Pathophysiol 2014; 5(4): 384-391 [PMID: 25400981 DOI: 10.4291/wjgp.v5.i4.384] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
18 Zhou X, Su J, Zhu L, Zhang G. Helicobacter pylori modulates cisplatin sensitivity in gastric cancer by down-regulating miR-141 expression. Helicobacter. 2014;19:174-181. [PMID: 24628843 DOI: 10.1111/hel.12120] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
19 Smith SM, O’Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol 2014; 20(29): 9912-9921 [PMID: 25110421 DOI: 10.3748/wjg.v20.i29.9912] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 73] [Article Influence: 9.0] [Reference Citation Analysis]
20 Oh B, Kim BS, Kim JW, Kim JS, Koh SJ, Kim BG, Lee KL, Chun J. The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial. Helicobacter. 2016;21:165-174. [PMID: 26395781 DOI: 10.1111/hel.12270] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 8.9] [Reference Citation Analysis]
21 Masjedizade A, Mohammadi MJ, Yazdankhah S, Roumi A, Shahriari A, Geravandi S. The effect of reducing the incidence of gastrointestinal complications in patients treated with aspirin, referred to Imam Hospital, of Ahvaz, Iran. Data Brief 2017;15:478-82. [PMID: 29062873 DOI: 10.1016/j.dib.2017.09.065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
22 Talebi Bezmin Abadi A. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017;8:123-30. [DOI: 10.1016/j.jgar.2016.11.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
23 Wang B, Lv ZF, Wang YH, Wang H, Liu XQ, Xie Y, Zhou XJ. Standard triple therapy for Helicobacter pylori infection in China: A meta-analysis. World J Gastroenterol 2014; 20(40): 14973-14985 [PMID: 25356059 DOI: 10.3748/wjg.v20.i40.14973] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
24 Ruggiero P, Censini S. Helicobacter pylori: A Brief History of a Still Lacking Vaccine. Diseases 2014;2:187-208. [DOI: 10.3390/diseases2020187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
25 Lv ZF, Wang FC, Zheng HL, Wang B, Xie Y, Zhou XJ, Lv NH. Meta-analysis: Is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection? World J Gastroenterol 2015; 21(8): 2522-2533 [PMID: 25741163 DOI: 10.3748/wjg.v21.i8.2522] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
26 Abu-Sini M, Mayyas A, Al-Karablieh N, Darwish R, Al-Hiari Y, Aburjai T, Arabiyat S, Abu-Qatouseh L. Synthesis of 1,2,3-Triazolo[4,5-h]quinolone Derivatives with Novel Anti-Microbial Properties against Metronidazole Resistant Helicobacter pylori. Molecules 2017;22:E841. [PMID: 28531095 DOI: 10.3390/molecules22050841] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
27 Metanat HA, Valizadeh SM, Fakheri H, Maleki I, Taghvaei T, Hosseini V, Bari Z. Comparison Between 10- and 14-Day Hybrid Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial. Helicobacter. 2015;20:299-304. [PMID: 25752357 DOI: 10.1111/hel.12202] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
28 Eslami M, Yousefi B, Kokhaei P, Jazayeri Moghadas A, Sadighi Moghadam B, Arabkari V, Niazi Z. Are probiotics useful for therapy of Helicobacter pylori diseases? Comparative Immunology, Microbiology and Infectious Diseases 2019;64:99-108. [DOI: 10.1016/j.cimid.2019.02.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
29 Harb AH, Chalhoub JM, Abou Mrad R, Sharara AI. Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2015;42:131-41. [PMID: 26011564 DOI: 10.1111/apt.13259] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
30 Jung SW, Thamphiwatana S, Zhang L, Obonyo M. Mechanism of antibacterial activity of liposomal linolenic acid against Helicobacter pylori. PLoS One. 2015;10:e0116519. [PMID: 25793403 DOI: 10.1371/journal.pone.0116519] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]